Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI
Since aspirin and clopidogrel are the widely and conventionally used drugs to treat acute myocardial infarction after percutaneous coronary intervention (PCI), it is important to explore potential risk factors of their resistance. The platelet aggregation rate with arachidonic acid (AA, PAg-AA%) and...
Main Authors: | Lijie Zhang PhD, MD, Ying Lv PhD, MD, Jianyu Dong PhD, MD, Nana Wang MSc, Zhan Zhan MSc, Yuan Zhao BSc, Shanshan Jiang PhD, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-03-01
|
Series: | Clinical and Applied Thrombosis/Hemostasis |
Online Access: | https://doi.org/10.1177/10760296221083674 |
Similar Items
-
Cross-Linking GPVI-Fc by Anti-Fc Antibodies Potentiates Its Inhibition of Atherosclerotic Plaque- and Collagen-Induced Platelet Activation
by: Janina Jamasbi, RPh, et al.
Published: (2016-04-01) -
Platelet Acetyl-CoA Carboxylase Phosphorylation
by: Shakeel Kautbally, MD, et al.
Published: (2019-09-01) -
Prognostic Implications of Immature Platelet Fraction at 5-Year Follow-up Among ACS Patients Treated With Dual Antiplatelet Therapy
by: Karolina Gumiężna MD, et al.
Published: (2024-01-01) -
PCI for Flush Occluded Right Coronary Artery
by: Jasleen Tiwana, MD, et al.
Published: (2023-08-01) -
High On-Treatment Platelet Reactivity in Patients Undergoing Complex Percutaneous Coronary Interventions
by: Lukáš Urban MD, PhD, et al.
Published: (2023-09-01)